Title: Preclinical study of the effect of endocannabinoid compounds on the treatment of sleep disorders

Biography:

Del Potter is a founder and director of Leef Holdings' new pharmaceutical division, ZBN Research. As CSO at ZBN Research. He has led the research effort to develop new endo-cannabinoid pharmaceutical and psychedelic formulations, initially addressing indications of insomnia and pain relief using major and minor Cannabinoid combinations. He has directed the development of new sublingual and transdermal delivery systems for endo-cannabinoid formulations. He recently provided expert testimony to the FDA regarding a ZBN Research’s new combination Cannabis drug for pain relief and for Opiate Use Disorder (OUD). He is a featured speaker at Cannatech and the Psytech Summit in Tel Aviv. 

Abstract

ZBN Research is engaged in preclinical studies of indications of insomnia and pain relief using novel formulations that include ancillary “entourage” compounds and ligands, combinations of cannabinoids, modified THC analogues and new transdermal and sublingual delivery systems that shorten the time to onset of effects and allow for sustained delivery of formulations. Recent findings from ZBN Research’s preclinical study of the effect of endocannabinoid compounds on the treatment of sleep disorders indicate the effectiveness of its new formulation compared to conventional sleep medications.